能倍乐 思力华噻托溴铵多少钱一盒

On May 26, 2017, Boehringer Ingelheim announced the results of a new analysis that provides further evidence that respiratory symptoms improved after the addition of AZA in a Phase III clinical development program and in a population of patients whose asthma symptoms remained uncontrolled on daily maintenance therapy. The results of these data analyzes were presented at the American Thoracic Society (ATS) International Conference in Washington, D.C., USA.

The landmark TIOSPIRTM trial verified that Respimat, Tiotropium bromide 2.5 μg (once a day, 2 puffs) and HandiHaler 18 μg have similar safety and effectiveness. Both forms of Respimat are in the leading position in the maintenance treatment of COPD.

Since Respimat and Tiotropium Bromide do not yet have domestic listing information, you need to consult a medical partner for the specific price.

The highly anticipated results of the 3-year trial were finally published (September 8, 2013) in the New England Journal of Medicine. The TIOSPIR trial was designed to compare the relative safety and effectiveness of Respimat Tiotropium 2.5 μg (once daily, 2 puffs) and the investigational dose of Respimat 1.25 μg (once daily, 2 puffs) with Respimat 18 μg. The specially designed TIOSPIR trial has appropriate sample size and follow-up time to analyze all-cause mortality and time to first acute exacerbation of COPD in a large population of COPD patients, and has broad inclusion criteria to truly reflect the real-world COPD patient population.

In the results discussion section, Professor Antonio Anzueto, professor of respiratory/emergency medicine at the University of Texas Health Science Center and trial investigator, said: "TIOSPIR is a landmark clinical trial that provides a large sample database to verify the safety and effectiveness of tiotropium bromide regardless of whether it is used with Sutra or Respimat.

More importantly, this large sample and rigorously designed clinical trial evidence shows that tiotropium bromide is safe for the majority of COPD patients, including those with a history of heart disease. The key message from this large-scale TIOSPIR study is that physicians can confidently choose this proven treatment for maintenance in patients with COPD of all severities. "

Adopting innovative technology, it is a new generation of effective SRIVA inhalers that patients can use under the advice of their doctor.

Recommended related hot articles: /newsDetail/85200.html